PDCD1 and glioblastoma: Additionally, BLZ945, a CSF-1 inhibitor, is tested as monotherapy and in combination with spartalizumab, a novel anti-PD1 monoclonal antibody, in solid cancers, including glioblastoma (NCT02829723).